VCYT Veracyte (VCYT) Q4 FY25 earnings call
Veracyte delivered a strong Q4 FY25, driven by robust performance in its core Decipher and Afirma testing businesses, which continue to show double-digit growth and market penetration. The company significantly exceeded its adjusted EBITDA margin target a year early, providing flexibility for strategic investments. Looking ahead, Veracyte is poised for multiple product launches in 2026, including TrueMRD for bladder cancer and Prosigna for breast cancer, which are expected to be key revenue drivers in 2027 and beyond.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
VCYT operating KPIs by quarter
| KPI | This call Dec 2025 Q4 FY25 | Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|---|
| Tests delivered Afirma | — | ~17.2KWe delivered approximately 17,200 tests in the first quarter, representing 12% year-over-year volume growth.Source: earnings call transcript | ~18.6KWe delivered another strong quarter with approximately 18,600 tests, representing 10% year-over-year volume growth and 18% revenue growth.Source: earnings call transcript | — |
| Tests delivered | ~48KWe grew total volume to approximately 48,000 tests, a 16% increase over the same period in 2024 and generated $52.6 million of cash from operations to end the quarter with $412.9 million of cash and cash equivalents on hand.Source: earnings call transcript | ~47.6KTotal volume increased to approximately 47,600 tests, up 17% compared to the same period in 2025, and we generated $35.2 million of cash from operations, ending the quarter with $439.1 million in cash, cash equivalents and short-term investments.Source: earnings call transcript | — | — |
| Testing volume | ~45.5KTotal testing volume was approximately 45,500 tests, an increase of 16% over the prior year period.Source: earnings call transcript | ~45.2KTotal testing volume was approximately 45,200 tests, representing 19% growth year-over-year. Testing ASP was $2,986, up 6% compared to the prior year and inclusive of approximately $4 million of prior period collections or PTCs.Source: earnings call transcript | 48.389KTotal testing volume was 48,389 tests, representing 14% year-over-year growth.Source: earnings call transcript | — |
| Testing ASP | ~$2,984Testing ASP was approximately $2,984, an increase of 4% compared to the prior year, driven primarily by the impact of higher prior period collections or PPCs.Source: earnings call transcript | $2,986Total testing volume was approximately 45,200 tests, representing 19% growth year-over-year. Testing ASP was $2,986, up 6% compared to the prior year and inclusive of approximately $4 million of prior period collections or PTCs.Source: earnings call transcript | $3,010Testing ASP was $3,010, up 4% to the prior year and inclusive of approximately $4.5 million of prior period collections or PTCs.Source: earnings call transcript | +0.8% |
| Normalized testing ASP | $2,875Normalized ASP was also higher at $2,875, a 1% increase compared to the prior year period after adjusting for the approximate impact of $5 million of PPCs in the quarter.Source: earnings call transcript | $2,900Excluding PTCs, normalized ASP increased 3% to $2,900, driven by continued strong collections.Source: earnings call transcript | ~$2,900Excluding PTCs, normalized ASP increased 3% to approximately $2,900, driven by the benefits of operational efforts put into place over the course of 2025, which have led to sustained pricing gains in the first half of this year.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.